Genscript Biotech Financials
| GNNSF Stock | USD 1.25 0.01 0.79% |
Genscript |
Understanding current and past Genscript Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Genscript Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Genscript Biotech's assets may result in an increase in income on the income statement.
Genscript Biotech Stock Summary
Genscript Biotech competes with Sino Biopharmaceutica, Defence Therapeutics, Aileron Therapeutics, and Enlivex Therapeutics. Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Jiangning Science Park, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.genscript.com |
| Phone | 86 25 5889 7288 |
| Currency | USD - US Dollar |
Genscript Biotech Key Financial Ratios
There are many critical financial ratios that Genscript Biotech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Genscript Biotech reports annually and quarterly.| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 | |||
| Beta | 1.35 | |||
| Z Score | 33.0 |
Genscript Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genscript Biotech's current stock value. Our valuation model uses many indicators to compare Genscript Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genscript Biotech competition to find correlations between indicators driving Genscript Biotech's intrinsic value. More Info.Genscript Biotech is rated # 5 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genscript Biotech's earnings, one of the primary drivers of an investment's value.Genscript Biotech Systematic Risk
Genscript Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Genscript Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Genscript Biotech correlated with the market. If Beta is less than 0 Genscript Biotech generally moves in the opposite direction as compared to the market. If Genscript Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genscript Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genscript Biotech is generally in the same direction as the market. If Beta > 1 Genscript Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Genscript Biotech December 15, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Genscript Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genscript Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genscript Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Genscript Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genscript Biotech's daily price indicators and compare them against related drivers.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 18.45 | |||
| Value At Risk | (0.72) |
Complementary Tools for Genscript Pink Sheet analysis
When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |